Tatsuya Takenouchi - Concepedia

Author

Tatsuya Takenouchi

Also Known As

S. Fukushima, T. TAKENOUCHI, T. Takenouchi, TATSUYA TAKENOUCHI, Tatsuya TAKENOUCHI, Tatsuya Takenouchi, Yasuhiro Nakamura, Yuji Okura

143

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

Niigata Cancer Center Hospital Shizuoka Cancer Center Shinshu University Kumamoto University Kyushu University

About

Tatsuya Takenouchi is an author at Niigata Cancer Center Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	21	1.4K
2	Health Sciences	3	3	73
3	Public Health	2	2	26
4	Biochemistry	1	1	18
5	Cell Biology	1	1	124

Tatsuya Takenouchi

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial Alexander Eggermont, Christian U. Blank, Mario Mandalà, The Lancet Oncology Surgical OncologyMedicineMelanomaImmunologyImmune Checkpoint Inhibitor	2021	364
A proposal for a TNM staging system for extramammary Paget disease: Retrospective analysis of 301 patients with invasive primary tumors Kuniaki Ohara, Yasuhiro Fujisawa, Koji Yoshino, Journal of Dermatological Science Surgical OncologyTnm Staging SystemTumoral PathologyMedicineSurgical Pathology	2016	148
Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, Cancer Science Cytokine BiomarkersImmunologyImmunoeditingImmunotherapeuticsImmunotherapy	2017	124
Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients Kaori Sakaizawa, Atsuko Ashida, Aya Uchiyama, Journal of Dermatological Science Japanese Melanoma PatientsMedicinePhotocarcinogenesisClinical CharacteristicsKit Mutations	2015	118
Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma Yasuhiro Fujisawa, Shusuke Yoshikawa, Akane Minagawa, Cancer Medicine	2019	106
Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041) Naoya Yamazaki, Tatsuya Takenouchi, Manabu Fujimoto, Cancer Chemotherapy and Pharmacology Phase 1BAnti-pd-1 Monoclonal AntibodyMedicineMelanomaImmunology	2017	86
Usefulness of docetaxel as first‐line chemotherapy for metastatic extramammary Paget's disease Koji Yoshino, Yasuhiro Fujisawa, Yoshio Kiyohara, The Journal of Dermatology	2015	79
Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients Yumi Nonomura, Atsushi Otsuka, Chisa Nakashima, OncoImmunology	2016	79
The role of sentinel lymph node biopsy in the management of invasive extramammary Paget's disease: Multi-center, retrospective study of 151 patients Yasuhiro Fujisawa, Koji Yoshino, Yoshio Kiyohara, Journal of Dermatological Science Retrospective StudySurgical OncologySurgical PathologyPathologyInvasive Extramammary Paget	2015	74
Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study Kenjiro Namikawa, Yoshio Kiyohara, Tatsuya Takenouchi, European Journal of Cancer	2018	72

Page 1